Stocktoria
ARTELO BIOSCIENCES, INC. ARTL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-13
ARTELO BIOSCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $5.4M | $6.0M | $5.7M | $4.3M | $3.8M |
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$9.4M |
| Interest expense | $194,000 | $0 | $0 | $5,000 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$9.4M |
| EPS (diluted) | $-12.52 | $-18.30 | $-3.14 | — | — |
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | — |
| Cash & equivalents | $600,000 | — | — | $6.9M | $12.2M |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M |
| Shareholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M |
Source: SEC EDGAR filings · CIK 0001621221 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.